{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:05:30Z","timestamp":1791317130298,"version":"4.3.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research","award":["26461418"],"award-info":[{"award-number":["26461418"]}]},{"name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research","award":["17K09924"],"award-info":[{"award-number":["17K09924"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T09:17:10Z","timestamp":1530609430000},"page":"315-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Extranodal NK\/T-cell lymphoma: Updates in biology and management strategies"],"prefix":"10.1016","volume":"31","author":[{"given":"Motoko","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Oguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2018.07.002_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.beha.2018.07.002_bib2","doi-asserted-by":"crossref","first-page":"790871","DOI":"10.1155\/2011\/790871","article-title":"Extranodal NK\/T-cell lymphoma: toward the identification of clinical molecular targets","volume":"2011","author":"Schmitt","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.beha.2018.07.002_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.beha.2013.04.006","article-title":"Molecular underpinning of extranodal NK\/T-cell lymphoma","volume":"26","author":"Huang","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2018.07.002_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","article-title":"The diagnosis and management of NK\/T-cell lymphomas","volume":"10","author":"Tse","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3960\/jslrt.17018","article-title":"Current treatment approaches for NK\/T-cell lymphoma","volume":"57","author":"Yamaguchi","year":"2017","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.beha.2018.07.002_bib6","first-page":"189","article-title":"Emerging insights on the pathogenesis and treatment of extranodal NK\/T cell lymphomas (ENKTL)","volume":"23","author":"Haverkos","year":"2017","journal-title":"Discov Med"},{"key":"10.1016\/j.beha.2018.07.002_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11899-018-0430-5","article-title":"NK\/T cell lymphoma: updates in therapy","volume":"13","author":"Suzuki","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.beha.2018.07.002_bib8","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib9","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2018.07.002_bib10","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","article-title":"CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance","volume":"89","author":"Drenou","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.V93.2.599","article-title":"P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833","volume":"93","author":"Egashira","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib12","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib13","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2006-07-033142","article-title":"Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK\/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"109","author":"Bossard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijrobp.2006.07.1387","article-title":"Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)\/T-cell lymphoma, nasal type","volume":"67","author":"Shim","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.beha.2018.07.002_bib15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2018.07.002_bib16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2018.07.002_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hon.2482","article-title":"Frequent expression of CD30 in extranodal NK\/T-cell lymphoma: potential therapeutic target for anti-CD30 antibody-based therapy","volume":"36","author":"Kawamoto","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5045\/br.2015.50.4.254","article-title":"Complete remission in CD30-positive refractory extranodal NK\/T-cell lymphoma with brentuximab vedotin","volume":"50","author":"Kim","year":"2015","journal-title":"Blood Res"},{"key":"10.1016\/j.beha.2018.07.002_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2018.07.002_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.beha.2018.07.002_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","article-title":"Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity","volume":"30","author":"Kim","year":"2012","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.beha.2018.07.002_bib22","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2018.07.002_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis","volume":"469","author":"Kim","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.beha.2018.07.002_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00277-016-2818-4","article-title":"Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK\/T-cell lymphoma, nasal type","volume":"96","author":"Jo","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2018.07.002_bib26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.beha.2018.07.002_bib27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1046\/j.1365-2141.1997.3223139.x","article-title":"Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma\/leukaemia","volume":"98","author":"Wong","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2018.07.002_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9440(10)65454-5","article-title":"Comparative genomic hybridization analysis of natural killer cell lymphoma\/leukemia. Recognition of consistent patterns of genetic alterations","volume":"155","author":"Siu","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beha.2018.07.002_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cyto.1069","article-title":"Comparative genomic hybridization study of nasal-type NK\/T-cell lymphoma","volume":"46","author":"Ko","year":"2001","journal-title":"Cytometry"},{"key":"10.1016\/j.beha.2018.07.002_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/gcc.20245","article-title":"Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma\/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk\/T-cell lymphoma, nasal type","volume":"44","author":"Nakashima","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.beha.2018.07.002_bib31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib32","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.1073\/pnas.1115128108","article-title":"PRDM1 is a tumor suppressor gene in natural killer cell malignancies","volume":"108","author":"Kucuk","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2018.07.002_bib33","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2011-04-346890","article-title":"Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses","volume":"118","author":"Karube","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib34","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib35","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib36","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/sj.onc.1205571","article-title":"Frequent mutations of Fas gene in nasal NK\/T cell lymphoma","volume":"21","author":"Takakuwa","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2018.07.002_bib37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2003.08.025","article-title":"P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK\/T-cell lymphoma from Hokkaido, Japan","volume":"35","author":"Takahara","year":"2004","journal-title":"Hum Pathol"},{"key":"10.1016\/j.beha.2018.07.002_bib38","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells","volume":"6","author":"Kucuk","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.beha.2018.07.002_bib39","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.18632\/oncotarget.3776","article-title":"Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2018.07.002_bib40","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ng.3358","article-title":"Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma","volume":"47","author":"Jiang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2018.07.002_bib41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/gcc.22348","article-title":"Frequent BCOR aberrations in extranodal NK\/T-Cell lymphoma, nasal type","volume":"55","author":"Dobashi","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.beha.2018.07.002_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/pin.12166","article-title":"Activated janus kinase 3 expression not by activating mutations identified in natural killer\/T-cell lymphoma","volume":"64","author":"Guo","year":"2014","journal-title":"Pathol Int"},{"key":"10.1016\/j.beha.2018.07.002_bib43","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3109\/10428194.2013.819577","article-title":"Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan","volume":"55","author":"Kimura","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2018.07.002_bib44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Bouchekioua","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2018.07.002_bib45","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","article-title":"Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nm.4456","article-title":"Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK\/T cell lymphoma","volume":"24","author":"Wen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.07.002_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib48","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2003-05-1401","article-title":"Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib52","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cncr.30697","article-title":"The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States","volume":"123","author":"Vargo","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2018.07.002_bib53","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1093\/annonc\/mds096","article-title":"Extranodal natural killer\/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis","volume":"23","author":"Ahn","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.beha.2018.07.002_bib55","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdx684","article-title":"Sequential chemotherapy\/radiotherapy was comparable with concurrent chemoradiotherapy for stage I\/II NK\/T-cell lymphoma","volume":"29","author":"Kwong","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib57","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib58","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2018.07.002_bib59","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib60","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1080\/10428194.2016.1180689","article-title":"Encouraging experience in the treatment of nasal type extra-nodal NK\/T-cell lymphoma in a non-Asian population","volume":"57","author":"Qi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2018.07.002_bib61","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.6541","article-title":"Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211","volume":"30","author":"Yamaguchi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib62","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib63","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/cas.13597","article-title":"Early disease progression in patients with localized NK\/T-cell lymphoma treated with concurrent chemoradiotherapy","volume":"109","author":"Yamaguchi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.beha.2018.07.002_bib64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11899-016-0355-9","article-title":"Extranodal NK\/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and european cases","volume":"11","author":"Haverkos","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.beha.2018.07.002_bib65","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.beha.2018.07.002_bib66","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib67","first-page":"140","article-title":"5-year follow-up of the SMILE phase II study for newly-diagnozed stage IV, relapsed or refractory extranodal NK\/T-cell lymphoma, nasal type","volume":"33","author":"Suzuki","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib68","doi-asserted-by":"crossref","first-page":"29092","DOI":"10.18632\/oncotarget.8647","article-title":"Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2018.07.002_bib69","doi-asserted-by":"crossref","first-page":"e2787","DOI":"10.1097\/MD.0000000000002787","article-title":"GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-Tolerated for newly diagnosed stage IV and relapsed\/refractory extranodal natural killer\/T-cell lymphoma, nasal type","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.beha.2018.07.002_bib70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdn542","article-title":"L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature","volume":"20","author":"Jaccard","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib71","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib72","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 5","key":"10.1016\/j.beha.2018.07.002_bib73","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib74","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: a CIBMTR analysis","author":"Kanate","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2018.07.002_bib75","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2018.07.002_bib76","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer\/T cell lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2018.07.002_bib77","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.3109\/10428194.2015.1037764","article-title":"High-dose therapy and autologous stem cell transplantation for extra-nodal NK\/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation","volume":"56","author":"Fox","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2018.07.002_bib78","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2018.07.002_bib79","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib80","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-17-0539","article-title":"Immunotherapy of lymphoma and myeloma: facts and hopes","volume":"24","author":"Pianko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2018.07.002_bib81","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.002_bib82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2018.07.002_bib85","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.002_bib86","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/mt.2015.91","article-title":"Long-term outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs","volume":"23","author":"Cho","year":"2015","journal-title":"Mol Ther"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T19:41:23Z","timestamp":1604518883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300240"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extranodal NK\/T-cell lymphoma: Updates in biology and management strategies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}